ES2087965T3 - Regimen contraceptivo. - Google Patents

Regimen contraceptivo.

Info

Publication number
ES2087965T3
ES2087965T3 ES91203282T ES91203282T ES2087965T3 ES 2087965 T3 ES2087965 T3 ES 2087965T3 ES 91203282 T ES91203282 T ES 91203282T ES 91203282 T ES91203282 T ES 91203282T ES 2087965 T3 ES2087965 T3 ES 2087965T3
Authority
ES
Spain
Prior art keywords
progestogen
equivalent
contraceptive
units
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91203282T
Other languages
English (en)
Inventor
Bennink Herman Jan Ti Coelingh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8205204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2087965(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2087965T3 publication Critical patent/ES2087965T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
  • Seeds, Soups, And Other Foods (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Supplying Of Containers To The Packaging Station (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Sludge (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)

Abstract

UN METODO Y REGIMEN ANTICONCEPTIVO QUE UTILIZA UNA CANTIDAD DE PROGESTOGENO INICIALMENTE MAYOR, LA CUAL DISMINUYE GRADUALMENTE A LO LARGO DEL PERIODO EN EL QUE SE ADMINISTRA EL ANTICONCEPTIVO. EL REGIMEN INCLUYE UNA COMBINACION EN VARIAS FASES Y UN EQUIPO ANTICONCEPTIVO QUE CONTIENE AL MENOS 21 UNIDADES DE DOSIFICACION SECUENCIALES DIARIAS DIVIDIDAS EN 3 FASE . LA PRIMERA FASE CONTIENE DE 6 A 8 UNIDADES DE DOSIFICACION, CADA UNA CON UN PROGESTOGENO EN UNA DOSIS EQUIVALENTE EN ACTIVIDAD PROGESTOGENICA A 75-150(MU)G DE DESOGESTREL Y UN ESTROGENO EN UNA DOSIS EQUIVALENTE EN ACTIVIDAD ESTROGENICA A 20-25(MU)G DE ETIMIL ESTRADIOL. LA SEGUNDA FASE CONTIENE DE 6 A 8 UNIDADES, CADA UNA DE LAS CUALES CONTIENE MENOS PROGESTOGENO QUE LAS UNIDADES DE LA DOSIS ANTERIOR, PERO TODAVIA TIENEN UN PROGESTOGENO EQUIVALENTE A 75-125(MU)G DE DESOGESTREL Y UN ESTROGENO EQUIVALENTE A 20 (MU)G DE ETINIL ESTRADIOL. LA TERCERA FASE CONTIENE MENOS PROGESTOGENO QUE EN LAS UNIDADES DE DOSIFICACION PREVIA, PERO AUN CONTIENE UN PROGESTOGENO EQUIVALENTE A 75-100 (MU)G DE DESOGESTRIL Y UN ESTROGENO EQUIVALENTE A 20 (MU)G DE ETIMIL ESTRADIOL. EL CONJUNTO PUEDE TAMBIEN INCLUIR OTRA FASE DE 4 A 7 UNIDADES DE DOSIFICACION SIN ESTEROIDE ANTICONCEPTIVO.
ES91203282T 1990-12-17 1991-12-12 Regimen contraceptivo. Expired - Lifetime ES2087965T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90203372 1990-12-17

Publications (1)

Publication Number Publication Date
ES2087965T3 true ES2087965T3 (es) 1996-08-01

Family

ID=8205204

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91203282T Expired - Lifetime ES2087965T3 (es) 1990-12-17 1991-12-12 Regimen contraceptivo.

Country Status (18)

Country Link
US (1) US5418228A (es)
EP (1) EP0491438B1 (es)
JP (1) JPH04290830A (es)
KR (1) KR100186780B1 (es)
CN (1) CN1036833C (es)
AT (1) ATE136219T1 (es)
AU (1) AU645637B2 (es)
CA (1) CA2057747C (es)
DE (1) DE69118494T2 (es)
DK (1) DK0491438T3 (es)
ES (1) ES2087965T3 (es)
FI (1) FI98985C (es)
GR (1) GR3020181T3 (es)
IE (1) IE62665B1 (es)
NO (1) NO179311C (es)
NZ (1) NZ240970A (es)
PT (1) PT99819B (es)
ZA (1) ZA919770B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227989A1 (de) * 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
MX9702162A (es) * 1994-09-22 1997-06-28 Akzo Nobel Nv Procedimiento para hacer unidades de dosis mediante granulacion en humedo.
CA2159419C (en) * 1994-10-17 2006-07-04 Pieter De Haan Solid pharmaceutical composition comprising an excipient capable of binding water
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
US5747480A (en) * 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive
AU2926897A (en) * 1996-05-08 1997-11-26 American Home Products Corporation Oral contraceptive
US6479475B1 (en) 1996-07-26 2002-11-12 Wyeth Oral contraceptive
US6451778B1 (en) 1996-07-26 2002-09-17 Wyeth Oral contraceptive
US5888543A (en) * 1996-07-26 1999-03-30 American Home Products Corporation Oral contraceptives
WO1998004267A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Progestin/estrogen oral contraceptive
CN1119999C (zh) * 1996-07-26 2003-09-03 惠氏公司 口服避孕药
US5858405A (en) * 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6511970B1 (en) * 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
FR2754179B1 (fr) 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
WO2001030355A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6028057A (en) * 1998-02-19 2000-02-22 Thorn Bioscience, Llc Regulation of estrus and ovulation in gilts
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US7459445B2 (en) * 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US7989436B2 (en) 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US7297688B2 (en) 2000-06-08 2007-11-20 Wyeth Starter kit for low dose oral contraceptives
JP2004140323A (ja) * 2002-08-20 2004-05-13 Sharp Corp 半導体レーザ装置およびその製造方法
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
MXPA05010871A (es) * 2003-04-11 2005-11-25 Barr Lab Inc Metodos para administrar estrogenos y progestinas.
CA2528545C (en) * 2003-06-13 2014-08-12 John Claude Savoir Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol
WO2005032558A1 (en) * 2003-10-01 2005-04-14 Janssen Pharmaceutica N.V. Extended triphasic contraceptive regimens
WO2005035717A2 (en) 2003-10-03 2005-04-21 Thorn Bioscience, Llc Process for the synchronization of ovulation for timed breeding without heat detection
EP1853272A1 (en) * 2005-02-03 2007-11-14 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
US20070197435A1 (en) * 2006-02-17 2007-08-23 Webel Stephen K Process for the synchronization of ovulation for timed breeding without heat detection
ES2734510T3 (es) 2008-10-08 2019-12-10 Agile Therapeutics Inc Administración transdérmica
CA2740004A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
US9198919B2 (en) 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
RU2568839C2 (ru) 2009-04-23 2015-11-20 ДжейБиЭс Юнайтид Энимал Хэлс II ЛЛК Способ и композиция для синхронизации времени осеменения
EP2925339B1 (en) 2012-11-28 2020-04-29 United-AH II, LLC Method for synchronizing time of insemination in gilts

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8001593A (nl) * 1980-03-18 1981-10-16 Akzo Nv Meerfasisch combinatiepreparaat voor orale anticonceptie.
US4530839A (en) * 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4962098A (en) * 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
IE61236B1 (en) * 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women

Also Published As

Publication number Publication date
US5418228A (en) 1995-05-23
GR3020181T3 (en) 1996-09-30
FI98985C (fi) 1997-09-25
IE914272A1 (en) 1992-06-17
KR100186780B1 (ko) 1999-05-01
NO914969L (no) 1992-06-18
FI915914A7 (fi) 1992-06-18
ATE136219T1 (de) 1996-04-15
NZ240970A (en) 1994-05-26
NO914969D0 (no) 1991-12-16
FI98985B (fi) 1997-06-13
PT99819A (pt) 1992-12-31
IE62665B1 (en) 1995-02-22
CN1036833C (zh) 1997-12-31
NO179311B (no) 1996-06-10
CA2057747A1 (en) 1992-06-18
DE69118494T2 (de) 1996-08-22
EP0491438B1 (en) 1996-04-03
NO179311C (no) 1996-09-18
CA2057747C (en) 2003-07-29
ZA919770B (en) 1992-09-30
DK0491438T3 (da) 1996-07-08
CN1062464A (zh) 1992-07-08
FI915914A0 (fi) 1991-12-16
PT99819B (pt) 2001-05-31
DE69118494D1 (de) 1996-05-09
AU8967991A (en) 1992-06-18
AU645637B2 (en) 1994-01-20
JPH04290830A (ja) 1992-10-15
EP0491438A1 (en) 1992-06-24
KR920011515A (ko) 1992-07-24

Similar Documents

Publication Publication Date Title
ES2087965T3 (es) Regimen contraceptivo.
ES2087964T3 (es) Contraceptivos orales bajos en estrogenos.
AU2001284052B2 (en) Contraception process and administration form for the same
AR028809A1 (es) Un metodo anticonceptivo y una unidad anticonceptiva oral trifasica
GB1490099A (en) Contraceptive method and pack
AU2001284052A1 (en) Contraception process and administration form for the same
BR9710566A (pt) M-todo anticoncepcional monof sico e um kit compreendendo uma combina-Æo de uma progestina e estrog-nio
WO1998004246A3 (en) Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen
ATE278406T1 (de) Orales contrazeptivum
ATE249222T1 (de) Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten
Smith The choice of the dose of oestrogen in a combined oral contraceptive

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 491438

Country of ref document: ES